Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Infinity Pharmaceuticals, Inc. (INFI)

0.64   -0.01 (-1.54%) 01-27 16:00
Open: 0.65 Pre. Close: 0.65
High: 0.6788 Low: 0.62
Volume: 447,402 Market Cap: 57(M)

Technical analysis

as of: 2023-01-27 4:45:30 PM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.89     One year: 1.05
Support: Support1: 0.58    Support2: 0.46
Resistance: Resistance1: 0.76    Resistance2: 0.89
Pivot: 0.66
Moving Average: MA(5): 0.64     MA(20): 0.64
MA(100): 0.89     MA(250): 0.91
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 32.6     %D(3): 40.3
RSI: RSI(14): 50
52-week: High: 1.75  Low: 0.43
Average Vol(K): 3-Month: 707 (K)  10-Days: 433 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ INFI ] has closed above bottom band by 29.8%. Bollinger Bands are 59% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.68 - 0.68 0.68 - 0.69
Low: 0.61 - 0.61 0.61 - 0.62
Close: 0.63 - 0.64 0.64 - 0.65

Company Description

Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Cambridge, Massachusetts.

Headline News

Sun, 29 Jan 2023
Prismo Metals Announces Definitive Agreement to Acquire Majority Interest in Hot Breccia Property in the Arizona Copper Belt - Yahoo Finance

Sat, 28 Jan 2023
Online streaming platform Enterinfi is enabling more creative stories to come to light that mainstream avenues - EIN News

Sat, 14 Jan 2023
What Does a Risk Analysis Say About Insured Finance (INFI) Saturday? - InvestorsObserver

Wed, 04 Jan 2023
Following 15% Rise Last Week, Infinity Pharmaceuticals Shareholders Still Down 72% Over Past Five Years - Simply Wall St

Mon, 14 Nov 2022
Infinity Pharmaceuticals (INFI) Stock Drops Over 20%: Details - Pulse 2.0

Mon, 14 Nov 2022
Infinity Pharmaceuticals Inc : Losses of 12 cents announced for third quarter - Kalkine Media

Financial Analysis

Price to Book Value: Underperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Outperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Underperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 89 (M)
% Held by Insiders 7.684e+007 (%)
% Held by Institutions 1.2 (%)
Shares Short 985 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -4.633e+007
EPS Est Next Qtl -0.21
EPS Est This Year -0.93
EPS Est Next Year -1.5
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 871.4
Return on Equity (ttm) -40.1
Qtrly Rev. Growth 2.5e+006
Gross Profit (p.s.) 53.98
Sales Per Share -357.7
EBITDA (p.s.) -2.51301e+007
Qtrly Earnings Growth -0.6
Operating Cash Flow 0 (M)
Levered Free Cash Flow -43 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio -0.1
Price to Book value 0
Price to Sales -0.01
Price to Cash Flow -6.56

Stock Dividends

Dividend 0
Forward Dividend 1.02e+006
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.